Drupal.behaviors.print = function(context) {window.print();window.close();}>
Vermillion's 2011 Financials Highlight OVA1 Sales Growth, Reimbursement Struggles
March 30, 2012
Vermillion's 2011 Financials Highlight OVA1 Sales Growth, Reimbursement Struggles
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Vermillion Planning Layoffs, Seeking New Partnerships in 2012
January 6, 2012 / ProteoMonitor
Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test
August 13, 2010 / ProteoMonitor
Vermillion Posts 11 Percent Rise in 2012 Revenues, 8 Percent Uptick in OVA1 Sales
February 22, 2013 / ProteoMonitor
Vermillion Reports Flat Q3 Revenues, First Peer-Reviewed Publication on Vasclir PAD Test
November 16, 2012 / ProteoMonitor
UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor